- Presents a poster identifying
tDCS effects for patients with AD and cognitively normal
people
- Showcases brain imaging treatment planning software for
electric brain stimulation Neurophet tESplan Plus
SEOUL,
South Korea, June 26,
2024 /PRNewswire/ -- Neurophet, an artificial
intelligence (AI) solution company for brain disease, announced
that it presented research study on brain stimulation simulation
related to Alzheimer's disease at OHBM (Organization for Human
Brain Mapping) Annual Meeting 2024.
Additionally, Neurophet showcased brain MRI analysis software
"Neurophet AQUA" and "Neurophet tESplan Plus". Neurophet tESplan
Plus is a product for research use that includes stroke affected
region analysis feature in the existing brain imaging treatment
planning software for electric brain stimulation "Neurophet
tES LAB", and is currently scheduled to be launched.
As the Alzheimer's disease treatment market grows, many studies
have reported that transcranial direct current stimulation (tDCS)
can help enhance cognitive function in patients with Alzheimer's
disease (AD). Previous studies have used the same brain electrical
stimulation method for patients with AD and cognitively normal
individuals (CN). In this case, the treatment effect may be reduced
because the target brain area cannot be sufficiently stimulated due
to brain atrophy.
Neurophet presented a poster on "Differences in transcranial
direct current stimulation-induced electrical fields according to
Alzheimer's disease and gender: An in-silico study." This study
investigated the differences in tDCS-induced electric field when
applying the same tDCS stimulation method for patients with AD and
cognitively normal individuals.
The study used Neurophet AQUA and Neurophet tES LAB to generate
a 3D model and conducted the simulation applying the same
stimulation method to both groups. The results showed that electric
field intensities by brain regions for AD groups are different with
CN groups.
Since previous studies have shown the magnitudes of
neurophysiological modulations induced by tDCS were significantly
associated with simulation-based electric field strengths,
differences in electric field intensities between CN and AD are
likely to lead to differences in clinical effectiveness. This
suggests the need for an optimized method of tDCS stimulation
considering anatomical differences in patients with AD, and it
demonstrates that optimized tDCS stimulation may help enhance tDCS
effectiveness and improve cognitive function.
"We have showcased our advanced brain stimulation simulation
products and research at OHBM, a traditional global conference that
brings scholars specializing in the brain," said CEO Jake Junkil
Been of Neurophet. "We also have had in-depth discussions with
researchers who are passionate about brain stimulation technology
for treating Alzheimer's disease as the market grows in
particular."
The OHBM is an international society dedicated to advancing the
understanding of the human brain using neuroimaging. It was first
held in Paris, France in 1995, and
it has been held in major cities around the world every June. This
year, it starts on the 23rd and runs until the 27th at
COEX in Seoul.
About Neurophet
Neurophet has specialized in developing solutions for diagnosis
support, treatment guides, and treatment devices targeting brain
diseases based on cutting-edge artificial intelligence (AI)
technology. The company was founded in 2016 by Jake Junkil Been,
CEO, and Donghyeon Kim, CTO, who developed the next-generation
neuro-navigation system.
Major products include brain MRI analysis software "Neurophet
AQUA", brain PET image analysis (PET tracer deposition) software
"Neurophet SCALE PET", brain imaging treatment planning software
for electric and magnetic brain stimulation "Neurophet tES/TMS
LAB".
Neurophet has set its top priority to helping patients suffering
from brain diseases. Based on expertise in neuroscience, Neurophet
will continue to challenge and grow to explore the human brain's
health and pioneer solutions for brain diseases with AI
technology.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurophet-to-present-brain-stimulation-simulation-study-at-ohbm-2024-302182395.html
SOURCE Neurophet